Nabriva Therapeutics PLC expected to post a loss of 67  cents a share - Earnings Preview

Nabriva Therapeutics

04/05/2021 22:16

* Nabriva Therapeutics PLC  NBRV.OQ   NBRV.O  is expected to
show a rise in quarterly revenue when it reports results on May
6.
* The Dublin, Ireland; Republic of-based company is expected to
report   a 185.2% increase in revenue to $2.25 million from $789
thousand a year ago, according to the estimate from one analyst,
based on Refinitiv data.
​* Refinitiv's mean analyst estimate for Nabriva Therapeutics
PLC is for a loss of 67 cents per share. For the same quarter
last year, the company reported a loss of $2.50 per share.
* The current average analyst rating on the shares is "hold" and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Nabriva
Therapeutics PLC is $6​, about 71.2% above​ its last closing
price of $1.73. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Dec. 31 2020              -0.95      -1.11     Missed  -16.8
 Sep. 30 2020  -0.90       -0.97      -0.90     Beat    7.7
 Jun. 30 2020  -1.61       -1.60      -1.40     Beat    12.5​
 Mar. 31 2020  -2.69       -2.64      -2.50     Beat    5.3
 Dec.          -3.24​      -3.32      -2.90     Beat    12.7​
 31​ 2019​                                              
 Sep. 30 2019  -2.82       -2.82      -2.40     Beat    15​
 Jun. 30 2019  -3.33       -3.35      -3.00     Beat    10.4
 Mar. 31 2019  -3.27       -3.22      -2.90     Beat    9.9
 This summary was machine generated May 4 at 21:16 GMT.  All
figures in US dollars unless otherwise stated